FDA approves new dose of Reclast for osteopenia

(Reuters) UPDATED 2009-06-04

The U.S. Food and Drug Administration has approved a new dosage of the osteoporosis drug Reclast. The new dose, which is one injection over two years, is approved to treat osteopenia, or low bone mass. The yearly dose of Reclast is already approved for the prevention of osteoporosis in the United States and Europe. Read full story >

See all Osteoporosis News

This helped!

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

We comply with the HONcode standard for
trustworthy health information: verify here.

By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.

Healthcentral.com is part of Remedy Health Media

FDA approves new dose of Reclast for osteopenia

People who read this also read...

What the community is saying...

Eat Healthy! Five Foods That Help Prevent Osteoporosis – and Five That Don’t

PJ Hamel